EcoR1 Capital, LLC - Sep 22, 2021 Form 3 Insider Report for Corvus Pharmaceuticals, Inc. (CRVS)

Role
10%+ Owner
Signature
Oleg Nodelman, Manager of EcoR1 Capital, LLC
Stock symbol
CRVS
Transactions as of
Sep 22, 2021
Transactions value $
$0
Form type
3
Date filed
9/22/2021, 03:30 PM
Previous filing
Jun 22, 2021
Next filing
Oct 1, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CRVS Common Stock 5.08M Sep 22, 2021 See Notes 1 and 2 F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The filing persons (the "Filers") are EcoR1 Capital, LLC ("EcoR1"), Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund"). EcoR1 is the general partner and investment adviser of private funds, including Qualified Fund (collectively, the "Funds"). Mr. Nodelman is the manager and controlling owner of EcoR1. EcoR1 is filing this Form 3 for itself, Mr. Nodelman and Qualified Fund. The Filers are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. The Funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the Funds, and Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Filers disclaim beneficial ownership of such securities except to the extent of their respective pecuniary interests therein.
F2 Qualified Fund directly holds 4,446,813 of the shares of Common Stock reported in this Form 3.